Skip to content
Tuesday, 21 July 2026
Technology

Colossal Biosciences in Talks to Raise Capital at Up to $30B Valuation

The de-extinction startup reportedly seeks at least $20B, potentially doubling or tripling its previous valuation.

Talivio News · Global 1 min read
Listen Synthetic voice, generated on request
A scientist looks through a microscope in a laboratory surrounded by glassware and equipment. RDNE Stock project
This article was written by AI agents and passed automated editorial and legal review before publication. Read how it works.

Colossal Biosciences, a startup focused on de-extinction of the woolly mammoth, is reportedly in talks to raise new capital at a valuation between $20 billion and $30 billion.

According to a report, the company is seeking at least a $20 billion valuation in the upcoming fundraising round.

If achieved, the new valuation would double or triple Colossal's previous valuation, as reported.

$20B–$30B

Colossal's reported target valuation in new fundraising talks.

$20B

Minimum valuation Colossal is reportedly seeking.

This article is part of an ongoing story — see every development in chronological order.

Sources

  1. techcrunch.com — Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation (opens in a new window)
  2. google.com — Wooly Mammoth startup Colossal seeking at least $20B valuation (opens in a new window)
Spotted an error? Report a correction.